In a letter to company#39;#39;s Managing Director Vishnukant Chaturbhuj Bhutada, the US health regulator said its inspectors, from February 13-20 and February 24-25, 2020, found significant deviations from standard manufacturing practices at company#39;#39;s Unit-IV at Polepally village in Mahabubnagar district.USFDA issues warning to Shilpa Medicare for CGMP violations at Telangana plant
In a letter to company#39;#39;s Managing Director Vishnukant Chaturbhuj Bhutada, the US health regulator said its inspectors, from February 13-20 and February 24-25, 2020, found significant deviations from standard manufacturing practices at company#39;#39;s Unit-IV at Polepally village in Mahabubnagar district.
Subscribe to:
Post Comments (Atom)
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The company#39;s vaccine candidate -Covaxin- has been developed in collaboration with the Indian Council of Medical Research (ICMR) - Natio...
No comments:
Post a Comment